We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.
Science
Leveraging a dedicated in-house team of scientific experts in antibody development, Paragon identifies novel therapeutic concepts with the potential to be best-in-class, and rapidly designs and advances them into the clinic.
Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.
Pipeline
Fueling a pipeline of best-in-class therapies for a range of diseases.
Our business model centers on bringing transformative therapies to patients as rapidly as possible. Our product candidate pipeline demonstrates our impressive progress. To date, we have generated multiple therapeutic candidates, 11 of which are being advanced in clinical development by several successful partner companies. The lead program entered the clinic less than two years from ideation.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR004 (APG777)
PR001 (APG808)
PR007 (APG990)
PR018 (APG333)
APG777 + APG990
APG777 + APG333
Rights/Partner
Apogee Therapeutics is the first company to be formed around assets discovered by and licensed from Paragon. Established in 2022, Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR011 (SPY001)
PR010 (SPY002)
PR014 (SPY003)
PR026 (SPY120)
PR022 (SPY130)
PR025 (SPY230)
Rights/Partner
Spyre Therapeutics is the second company to be formed around assets discovered by and licensed from Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR035 (ORKA-001)
PR029 (ORKA-002)
PR059 (ORKA-003)
Rights/Partner
Oruka Therapeutics is the third company to be formed around assets discovered by and licensed from Paragon. Established in 2024, Oruka is advancing a pipeline of potentially best-in-class biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR030 (JADE-001)
PR041 (JADE-002)
PR050 (JADE-003)
Rights/Partner
Jade Biosciences is the fourth company to be formed around assets discovered by and licensed from Paragon. Jade is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR054 (CR-001)
PR062 (CR-002)
PR023 (CR-003)
Rights/Partner
Crescent Biopharma is the fifth company to be formed around assets discovered by and licensed from Paragon. Crescent is advancing a pipeline of precision-engineered molecules designed to advance care for patients with solid tumors.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR002
PR013
Rights/Partner
Undisclosed
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
Multiple internal programs
Rights/Partner
Partners
Driving rapid progress and patient impact.
Our scientific approach and expertise have generated the assets that serve as the foundation for several successful companies devoted to bringing transformative treatments to patients living with significant unmet medical conditions.
ABOUT APOGEE THERAPEUTICS
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit apogeetherapeutics.com.
ABOUT SPYRE THERAPEUTICS
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, please visit spyre.com.
ABOUT ORUKA THERAPEUTICS
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
ABOUT JADE BIOSCIENCES
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
ABOUT CRESCENT BIOPHARMA
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Team
Dedicated experts with a passion for improving health outcomes.
Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.
Susanna High, MBA
Chief Executive Officer
View Bio
Mary Beth DeLena, J.D.
Chief Legal Officer
View Bio
Keri Lantz
Chief Financial Officer
View Bio
Hussam Shaheen, Ph.D.
Chief Scientific Officer
View Bio
Damon Banks, Ph.D., J.D.
Senior Vice President, Legal Affairs
View Bio
Neta Batscha
Senior Vice President, Corporate Strategy And Operations
View Bio
Kelly Jackson
Senior Vice President, Partner Company Leadership and Chief of Staff
View Bio
Michael Meehl, Ph.D.
Senior Vice President, Biologics Research
View Bio
Jason Oh, Ph.D.
Senior Vice President, Biology
View Bio
Shawn Russell, Ph.D.
Senior Vice President, Chemistry, Manufacturing, And Controls
View Bio
Cyrus Stacey
Senior Vice President, Quality
View Bio
Ghassan Fayad, Ph.D.
Vice President, Translational Sciences
View Bio
Mark Heffernan
Executive Director, Corporate Controller
View Bio
Joe Russo
Executive Director, Finance Planning And Analysis
View Bio
Archit Sheth-Shah
Executive Director, Portfolio Strategy
View Bio
Melissa Donnarummo
Senior Director, Project Accounting
View Bio
Byron Kwan, Ph.D.
Senior Director, Biotherapeutics
View Bio
Danielle Malloy
Senior Director, Legal Affairs
View Bio
Ken Michaud
Senior Director, Information Technology
View Bio
Daniel Rios, Ph.D.
Senior Director, Biology
View Bio
Russell Sanderson, Ph.D.
Senior Director, Bioanalytical Sciences
View Bio
Rita Vaz, Ph.D.
Senior Director, Program and Alliance Management
View Bio
Melissa Conerly, Ph.D.
Director of Biology, ADC Technology
View Bio
Lauren Gillis
Director, Human Resources
View Bio
Jamie Harrington
Director, Formulations
View Bio
Pamela Howley
Director, Chemistry, Manufacturing, and Controls
View Bio
Bernard Liu, Ph.D.
Director, Biologics
View Bio
Kalyan Pande, Ph.D.
Director, Biology
View Bio
M. Murshid Alam, Ph.D.
Associate Director, Biology
View Bio
Parker Johnson, Ph.D.
Associate Director, Biologics
View Bio
Byong Ha Kang, Ph.D.
Associate Director, Biology
View Bio
Ericka Koos, MBA
Associate Director, Assistant Controller
View Bio
Lauren Maslin, Ph.D.
Associate Director, Portfolio Strategy
View Bio
Jake Milligan, Ph.D.
Associate Director, Biologics
View Bio
Joana Ministro, Ph.D.
Associate Director, Program and Alliance Management
View Bio
Soraia Oliveira, Ph.D.
Associate Director, Program and Alliance Management
View Bio
Eric Pohle
Associate Director, Financial Planning and Analysis
View Bio
Andrew Schirmer
Associate Director, Manufacturing
View Bio
Jacqueline Heiss, Ph.D., J.D.
Patent Counsel
View Bio
Erin Clark, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Alex Mitkas, Ph.D.
Principal Scientist, Drug Metabolism and Pharmacokinetics
View Bio
Kevin Kramer, Ph.D.
Senior Scientist
View Bio
Jing Gong, Ph.D.
Senior Associate, Portfolio Strategy
View Bio
Fabiana Zappala, Ph.D.
Senior Associate, Portfolio Strategy
View Bio
Inês Castro, Ph.D.
Senior Manager, Program and Alliance Management
View Bio
Veronica French
Senior Manager, Executive Administration
View Bio
Joana Vidal Silva
Senior Manager, Program and Alliance Management
View Bio
Jodie Raye
SENIOR ACCOUNTANT
View Bio
Jill Igoe
ACCOUNTS PAYABLE MANAGER
View Bio
Alison Fiore
ADMINISTRATIVE ASSISTANT
View Bio
Sophia Medina
ADMINISTRATIVE ASSISTANT
View Bio
About Us
Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics and complex biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies.
News
The latest Paragon news and developments.
- All
- Paragon News
- Partner News
- Sort by
- Newest
- Oldest
- Paragon Therapeutics
- Spyre Therapeutics
- apogee Therapeutics
- Oruka Therapeutics
- Jade Biosciences
- Crescent Biopharma
Join Us
Be a part of our innovative team.
We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.
VALUES
Powered by our dedication and commitment to improve the lives of patients with high unmet needs.
Our values reflect who we are and guide our actions and decisions, empowering everyone to contribute meaningfully to our shared purpose.
Team First
We respect and value each other’s ideas and contributions. We achieve more by working together.
Uphold a High Bar
We build best-in-class therapies that are impactful for patients. We aim to improve with every iteration, striving for long-term excellence.
Experimentalists at Heart
We are open-minded and data-driven. We constantly adapt and evolve as new information emerges.
Bias Toward Action
We work with a sense of urgency to advance therapeutic programs to the clinic rapidly and efficiently.
Keep It Fun
We celebrate our successes and our opportunities to learn. We are passionate about our work and our play.